
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Metastatic Non-Small Cell Lung Cancer with Alexander Drilon, MD
Case Scenario 2:
SR is a 58 year-old female, former smoker 20 PPY (stopped smoking 5 years ago), presents with cough and SOB. She experienced an unintended 10 lb weight loss over a 3-month period.
Patient was started on carboplatin/paclitaxel/bevacizumab for 4 cycles. Patient showed partial response and was continued on bevacizumab until progression.


